inclusion criteria: 1. participant has laboratory-confirmed sars-cov-2 infection as determined by reverse transcriptase polymerase chain reaction (rt-pcr) or other approved clinical testing prior to randomization. 2. participant is hospitalized in relation to covid-19, requiring supplemental oxygen to maintain spo2 at a safe level (who level 3 \& 4). 3. participant is capable of giving signed informed consent 4. participant is male or female. all females of childbearing potential, including pregnant females, must consent to urine pregnancy testing at screening to be eligible for the study.

inclusion criteria: 1. participant has laboratory-confirmed sars-cov-2 infection as determined by reverse transcriptase polymerase chain reaction (rt-pcr) or other approved clinical testing prior to randomization. 2. participant is hospitalized in relation to covid-19, requiring supplemental oxygen to maintain spo2 at a safe level (who level 3 \& 4). 3. participant is capable of giving signed informed consent 4. participant is male or female. all females of childbearing potential, including pregnant females, must consent to urine pregnancy testing at screening to be eligible for the study.

inclusion criteria: participant has laboratory-confirmed sars-cov-2 infection as determined by reverse transcriptase polymerase chain reaction (rt-pcr) or other approved clinical testing prior to randomization. participant is hospitalized in relation to covid-19, requiring supplemental oxygen to maintain spo2 at a safe level (who level 3 & 4). participant is capable of giving signed informed consent participant is male or female. all females of childbearing potential, including pregnant females, must consent to urine pregnancy testing at screening to be eligible for the study.

inclusion criteria: participant has laboratory-confirmed sars-cov-2 infection as determined by reverse transcriptase polymerase chain reaction (rt-pcr) or other approved clinical testing prior to randomization. participant is hospitalized in relation to covid-19, requiring supplemental oxygen to maintain spo2 at a safe level (who level 3 & 4). participant is capable of giving signed informed consent participant is male or female. all females of childbearing potential, including pregnant females, must consent to urine pregnancy testing at screening to be eligible for the study.

inclusion criteria: 1. participant has laboratory-confirmed sars-cov-2 infection as determined by reverse transcriptase polymerase chain reaction (rt-pcr) or other approved clinical testing prior to randomization. 2. participant is hospitalized in relation to covid-19, requiring supplemental oxygen to maintain spo2 at a safe level (who level 3 & 4). 3. participant is capable of giving signed informed consent 4. participant is male or female. all females of childbearing potential, including pregnant females, must consent to urine pregnancy testing at screening to be eligible for the study.

inclusion criteria: 1. participant has laboratory-confirmed sars-cov-2 infection as determined by reverse transcriptase polymerase chain reaction (rt-pcr) or other approved clinical testing prior to randomization. 2. participant is hospitalized in relation to covid-19, requiring supplemental oxygen to maintain spo2 at a safe level (who level 3 & 4). 3. participant is capable of giving signed informed consent 4. participant is male or female. all females of childbearing potential, including pregnant females, must consent to urine pregnancy testing at screening to be eligible for the study.

inclusion criteria: 1. participant has laboratory-confirmed sars-cov-2 infection as determined by reverse transcriptase polymerase chain reaction (rt-pcr) or other approved clinical testing prior to randomization. 2. participant is hospitalized in relation to covid-19, requiring supplemental oxygen to maintain spo2 at a safe level (who level 4). 3. participant is capable of giving signed informed consent 4. participant is male or female. all females of childbearing potential, including pregnant females, must consent to urine pregnancy testing at screening to be eligible for the study.

inclusion criteria: 1. participant has laboratory-confirmed sars-cov-2 infection as determined by reverse transcriptase polymerase chain reaction (rt-pcr) or other approved clinical testing prior to randomization. 2. participant is hospitalized in relation to covid-19, requiring supplemental oxygen to maintain spo2 at a safe level (who level 4). 3. participant is capable of giving signed informed consent 4. participant is male or female. all females of childbearing potential, including pregnant females, must consent to urine pregnancy testing at screening to be eligible for the study.